Bartolacci C, Andreani C, Vale G, Berto S, Melegari M, Crouch A, et al. Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer. Nat Commun. 2022;13:4327 pubmed publisher

Masgras I, Cannino G, Ciscato F, Sanchez Martin C, Darvishi F, Scantamburlo F, et al. Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD+ and SIRT3. Cell Death Differ. 2022;: pubmed publisher

Merkle J, Breunig M, Schmid M, Allgöwer C, Krüger J, Melzer M, et al. CDKN2A-Mutated Pancreatic Ductal Organoids from Induced Pluripotent Stem Cells to Model a Cancer Predisposition Syndrome. Cancers (Basel). 2021;13: pubmed publisher

Griesmann H, Mühl S, Riedel J, Theuerkorn K, Sipos B, Esposito I, et al. CUX1 Enhances Pancreatic Cancer Formation by Synergizing with KRAS and Inducing MEK/ERK-Dependent Proliferation. Cancers (Basel). 2021;13: pubmed publisher

Li R, Ng T, Wang S, Prytyskach M, Rodell C, Mikula H, et al. Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer. Nat Nanotechnol. 2021;16:830-839 pubmed publisher

Breunig M, Merkle J, Wagner M, Melzer M, Barth T, Engleitner T, et al. Modeling plasticity and dysplasia of pancreatic ductal organoids derived from human pluripotent stem cells. Cell Stem Cell. 2021;28:1105-1124.e19 pubmed publisher

Yang H, Song B, Sim B, Jung Y, Chae U, Lee D, et al. Establishment and Characterization of Immortalized Miniature Pig Pancreatic Cell Lines Expressing Oncogenic K-RasG12D. Int J Mol Sci. 2020;21: pubmed publisher

Tsang T, Posimo J, Gudiel A, Cicchini M, Feldser D, Brady D. Copper is an essential regulator of the autophagic kinases ULK1/2 to drive lung adenocarcinoma. Nat Cell Biol. 2020;22:412-424 pubmed publisher

Dai E, Han L, Liu J, Xie Y, Kroemer G, Klionsky D, et al. Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein. Autophagy. 2020;:1-15 pubmed publisher

Inoue S, Hirota Y, Ueno T, Fukui Y, Yoshida E, Hayashi T, et al. Uterine adenomyosis is an oligoclonal disorder associated with KRAS mutations. Nat Commun. 2019;10:5785 pubmed publisher

Kalvala A, Wallet P, Yang L, Wang C, Li H, Nam A, et al. Phenotypic Switching of Naïve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRAS. J Clin Med. 2019;8: pubmed publisher

Liu S, Hong Y, Markowiak S, Sanchez R, Creeden J, Nemunaitis J, et al. BIRC5 is a target for molecular imaging and detection of human pancreatic cancer. Cancer Lett. 2019;457:10-19 pubmed publisher

Bydoun M, Sterea A, Liptay H, Uzans A, Huang W, Rodrigues G, et al. S100A10, a novel biomarker in pancreatic ductal adenocarcinoma. Mol Oncol. 2018;12:1895-1916 pubmed publisher

Li Z, Zhu S, Chen X, Zhu J, Chen Q, Zhang Y, et al. ARID1A suppresses malignant transformation of human pancreatic cells via mediating senescence-associated miR-503/CDKN2A regulatory axis. Biochem Biophys Res Commun. 2017;493:1018-1025 pubmed publisher

Kauke M, Traxlmayr M, Parker J, Kiefer J, Knihtila R, McGee J, et al. An engineered protein antagonist of K-Ras/B-Raf interaction. Sci Rep. 2017;7:5831 pubmed publisher

Zhong X, Zheng L, Shen J, Zhang D, Xiong M, Zhang Y, et al. Suppression of MicroRNA 200 Family Expression by Oncogenic KRAS Activation Promotes Cell Survival and Epithelial-Mesenchymal Transition in KRAS-Driven Cancer. Mol Cell Biol. 2016;36:2742-2754 pubmed publisher

Madureira P, Bharadwaj A, Bydoun M, Garant K, O Connell P, Lee P, et al. Cell surface protease activation during RAS transformation: Critical role of the plasminogen receptor, S100A10. Oncotarget. 2016;7:47720-47737 pubmed publisher

Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely C, et al. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med. 2015;21:1038-47 pubmed publisher